Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31078581 | 1.00 | S1PR2 (0.59) | S1PR2CYP1A2POLBKDM4EALDH1A1 | |
| SCHEMBL862340 | 0.87 | CYP1A2 (0.66) | S1PR2CYP1A2POLBKDM4EALDH1A1 | |
| SCHEMBL787591 | 0.86 | CYP1A2 (0.51) | S1PR2CYP1A2POLBKDM4EALDH1A1 | |
| SCHEMBL31127029 | 0.86 | CYP1A2 (0.51) | S1PR2CYP1A2POLBKDM4EALDH1A1 | |
| SCHEMBL2823270 | 0.83 | CYP1A2 (0.51) | S1PR2CYP1A2POLBKDM4EALDH1A1 | |
| SCHEMBL917429 | 0.83 | CYP1A2 (0.51) | S1PR2CYP1A2POLBKDM4EALDH1A1 | |
| SCHEMBL3403855 | 0.82 | NQO2 (0.47) | S1PR2CYP1A2KDM4EALDH1A1MAPT | |
| SCHEMBL29427729 | 0.82 | NQO2 (0.47) | S1PR2CYP1A2KDM4EALDH1A1MAPT | |
| SCHEMBL3853608 | 0.81 | KDM4E (0.51) | S1PR2CYP1A2POLBKDM4EALDH1A1 | |
| SCHEMBL20579411 | 0.81 | CYP1A2 (0.46) | S1PR2CYP1A2POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| CN-114364667-B | 3-Substituted piperidines for Cbl-b inhibition and use of Cbl-b inhibitors in combination with cancer vaccines and/or oncolytic viruses | 紐力克斯治疗公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240409555-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-114206855-B | Cyanocyclobutyl compounds for Cbl-b inhibition and application thereof | 紐力克斯治疗公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240293458-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | NURIX THERAPEUTICS, INC. | 2024-09-05 | — | — | US | disclosed |
| US-12049471-B2 | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-11951133-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11530229-B2 | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof | NURIX THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220378839-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-12-01 | — | — | US | disclosed |
| EP-2195311-B1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| CN-101965346-A | Novel pyrimidine-pyridine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-02-02 | — | — | CN | disclosed |
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-12-30 | — | — | US | disclosed |
| EP-2262800-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2252609-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-24 | — | — | EP | disclosed |
| EP-2195311-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009109872-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109907-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049471-B2 | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof | CBLB, CBL, CBLC | S1PR2 4407/4885CYP1A2 4606/4885POLB 265/4885 |
| US-20220378839-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | CBLB, CBL, CBLC | S1PR2 3161/4885CYP1A2 4676/4885POLB 356/4885 |
| US-11951133-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | S1PR2 3161/4885CYP1A2 4676/4885POLB 356/4885 |
| US-20240409555-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | CBLB, CBL, CBLC | S1PR2 4407/4885CYP1A2 4606/4885POLB 265/4885 |
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | IL2, FCGRT, CD4 | S1PR2 91/4885CYP1A2 420/4885POLB 4155/4885 |
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | S1PR2 3161/4885CYP1A2 4676/4885POLB 356/4885 |
| US-11530229-B2 | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof | CBLB, CBL, CBLC | S1PR2 4407/4885CYP1A2 4606/4885POLB 265/4885 |
| US-20240293458-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | CBLB, CBL, CBLC | S1PR2 3161/4885CYP1A2 4676/4885POLB 356/4885 |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | S1PR2 639/4885CYP1A2 2635/4885POLB 1308/4885 |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | CBLB, CBL, CBLC | S1PR2 4407/4885CYP1A2 4606/4885POLB 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.